Sensitization of tumor cells by targeting histone deacetylases

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Epigenetic modifications, specifically histone acetylation, play a crucial role in regulating gene expression and cellular processes like tumor growth and apoptosis.
• Dysregulation of these epigenetic mechanisms can contribute to the development of cancer drug resistance.
• Histone deacetylase (HDAC) inhibitors are a class of drugs that modulate histone acetylation and have demonstrated antitumor potential.

Purpose of the Study:

• To explore the role of epigenetic mechanisms, particularly HDAC inhibitors, in overcoming cancer drug resistance.
• To review preclinical combination strategies involving HDAC inhibitors and their impact on cancer cell apoptosis and drug sensitivity.
• To investigate the potential of targeting HDACs, including HDAC6, for novel cancer therapeutic approaches.

Main Methods:

• Review of preclinical studies investigating the combination of HDAC inhibitors with conventional and targeted anticancer agents.
• Analysis of reported therapeutic effects and mechanisms of sensitization in various cancer models.
• Exploration of the role of HDAC6 in modulating non-histone protein function relevant to cancer regulation.

Main Results:

• Preclinical studies demonstrate promising therapeutic effects when HDAC inhibitors are combined with DNA damaging agents, taxanes, targeted therapies, death receptor agonists, and hormonal therapies.
• These combination strategies enhance cancer cell susceptibility to apoptosis and improve overall drug sensitivity.
• HDAC6 has been identified as a potential therapeutic target due to its role in regulating critical non-histone protein functions.

Conclusions:

• HDAC inhibitors represent a valuable strategy for overcoming cancer drug resistance by promoting apoptosis and enhancing sensitivity to other therapies.
• Combination therapies involving HDAC inhibitors show significant potential in preclinical settings across various treatment modalities.
• Further elucidation of the mechanisms underlying HDAC inhibitor-mediated sensitization is crucial for optimizing their therapeutic application and improving patient outcomes.